The new perioperative strategy in gastric cancer involves incorporating immunotherapy into the existing chemotherapy regimen to improve outcomes for patients with resectable gastric and gastroesophageal junction cancers. These cancers are highly aggressive, with high recurrence rates even after surgery and chemotherapy.
The new perioperative strategy in gastric cancer involves incorporating immunotherapy into the existing chemotherapy regimen to improve outcomes for patients with resectable gastric and gastroesophageal junction cancers. These cancers are highly aggressive, with high recurrence rates even after surgery and chemotherapy. The current standard treatment, known as the FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel), has shown survival benefits but remains insufficient to address the high recurrence rates.
To address this gap, the phase 3 MATTERHORN clinical trial investigated the addition of durvalumab, an immune checkpoint inhibitor targeting PD-L1 (programmed death-ligand 1), to the FLOT regimen. Durvalumab is designed to enhance the immune system's ability to recognize and attack cancer cells.
Early results from the MATTERHORN trial have been promising, showing higher response rates and a potential survival benefit when durvalumab is added to the FLOT chemotherapy regimen. This suggests that immunotherapy, when combined with standard perioperative chemotherapy, could significantly improve outcomes for patients with resectable gastric and gastroesophageal junction cancers.
In summary, the new perioperative strategy highlights the potential of integrating immunotherapy (durvalumab) with FLOT chemotherapy to reduce recurrence rates and improve survival in patients with these challenging cancers. This approach represents a significant advancement in the treatment landscape for gastric cancer.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.